CLOs on the Move

Ggg Inc

www.ggg.com

 
Ggg Inc is a Chatfield, MN-based company in the Business Services sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.ggg.com
  • 14070 Highway 52 SE
    Chatfield, MN USA 55923
  • Phone: 507.867.1666

Executives

Name Title Contact Details

Similar Companies

Springfield Travel Service

Springfield Travel Service is a Springfield, MO-based company in the Business Services sector.

Pratt Visual Solutions, a Vomela Company

Pratt Visual Solutions, a Vomela Company is a Indianapolis, IN-based company in the Business Services sector.

Technology Diagnostics Corp

Technology Diagnostics Corp is a Norcross, GA-based company in the Business Services sector.

Rocketrip

Rocketrip cuts a company`s travel costs by incentivizing employees to spend less on their trips. When employees get to keep a portion of the savings they generate, they start to treat the company`s money like it`s their own. Rocketrip`s software combines real-time travel prices, company policy, and a suite of patented algorithms to set customized budgets and predict what a trip should cost. Business travelers beat their budgets by making cost-conscious choices like booking in advance, selecting a cheaper hotel, or staying with friends. The company saves money, and the employee earns actual rewards. Rocketrip provides comprehensive reporting and seamlessly integrates into any existing corporate and expense technology stack.

Cellerant

Cellerant Therapeutics is a clinical stage biotechnology company focused on developing human stem cell and antibody therapies for oncology applications and blood-related disorders. Cellerant`s programs include: CLT-008, an off-the-shelf cellular immunotherapy, under evaluation in a multicenter, open-label, randomized, controlled Phase 2 clinical trial in patients with de novo AML; CSC030-ADC, a preclinical monoclonal antibody drug conjugate that selectively targets and kills leukemic stem and blast cells responsible for initiating and maintaining disease; and CSC012, a preclinical monoclonal antibody targeting leukemic and pre-leukemic stem cells for acute leukemias and myelodysplastic syndromes. The Company is also developing next generation CAR product candidates leveraging its proprietary immunocellular therapy and antibody discovery and development platform.